Why this drug is different from everything before it

If you've been managing hot flashes without HRT, your options until recently were limited. SSRIs and SNRIs reduce frequency by around 50% but come with sexual side effects and antidepressant discontinuation issues. Gabapentin helps but causes sedation. Lifestyle changes help, but not for severe symptoms. The unmet need has been real.

Elinzanetant works by targeting KNDy neurons in the hypothalamus — the brain cells that regulate body temperature. When estrogen declines, these neurons become overactive and trigger the thermoregulatory cascade that causes a hot flash. Elinzanetant blocks both NK1 and NK3 receptors on those neurons, calming the circuit directly. It doesn't replace estrogen. It turns down the heat signal.

73%
reduction in moderate-to-severe hot flash frequency at 12 weeks in the OASIS-3 trial (vs 47% for placebo)
60mg
once-daily oral capsule dose — no patches, injections, or complex schedules
4 wks
point at which significant symptom reduction was first confirmed in OASIS-1 and OASIS-2 co-primary endpoints

What the OASIS trials actually showed

Three Phase III trials — OASIS-1, OASIS-2, and OASIS-3 — enrolled 796 menopausal women and ran from 12 to 52 weeks. Both frequency and severity of hot flashes dropped significantly versus placebo from week 4. At 12 weeks, participants also reported better sleep quality and improved menopause-specific quality-of-life scores.

The long-term OASIS-3 data is particularly relevant: the 73% reduction held over 52 weeks without evidence of tolerance developing. That kind of sustained efficacy over a year is important — it means this isn't just a short-term fix.

Side effects were generally mild. Headache, fatigue, dizziness, and drowsiness were most commonly reported. No liver toxicity signals were identified. This is genuinely a cleaner safety profile than some of the off-label options women have been using for years.

Research Evidence

The OASIS-3 52-week long-term trial confirmed both safety and efficacy across a broad population of menopausal women. Elinzanetant also improved scores on the Menopause-Specific Quality of Life questionnaire and the Patient Global Impression of Change scale, indicating benefits beyond just hot flash frequency reduction.

Who is it actually for?

Elinzanetant is designed for women with moderate-to-severe vasomotor symptoms who can't or prefer not to use hormone therapy. This includes breast cancer survivors, women with estrogen-sensitive conditions, and those who've had unsatisfactory results with SSRIs or other existing options.

For women who can safely use HRT, estrogen-based therapy still has a broader evidence base — particularly for bone density, cardiovascular markers, and vaginal atrophy. Elinzanetant is not a replacement for HRT in women for whom HRT would be appropriate. It's a new option for those it isn't.

What to discuss with your OB-GYN or menopause specialist

  • ✓
    Ask whether you're a candidate based on your symptom severity. Elinzanetant is approved for moderate-to-severe hot flashes — not mild ones. Your doctor will want to assess frequency and impact on sleep and daily function.
  • ✓
    Mention your medication list. As a newer drug, elinzanetant's interaction profile is still being characterized. Full medication review is standard before starting.
  • ✓
    Ask about cost and insurance coverage. As a recently approved drug, coverage is variable. Your doctor may need to provide documentation of medical necessity or HRT contraindication.
💊

Menopause Specialist's Note

Elinzanetant fills a genuine gap in menopause care. For women with estrogen-sensitive cancers who've been struggling with severe hot flashes on inadequate alternatives, this represents a meaningful advance. That said, no drug works for everyone. If symptoms don't improve within 8 weeks, a frank conversation with your doctor about alternatives is reasonable. This is a discussion worth having — not a reason to quietly stop treatment.

Medical Disclaimer: This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Sources

  1. FDA approves elinzanetant (Lynkuet) for vasomotor menopausal symptoms. (Oct 2025). Contemporary OB/GYN. contemporaryobgyn.net
  2. Bayer. Lynkuet FDA Approval Press Release. (Oct 2025). bayer.com
  3. OASIS-3 52-week trial results. Bayer elinzanetant data. (2025). UPI Health. upi.com
  4. Nonhormonal therapies transform menopause care in 2025. Contemporary OB/GYN. contemporaryobgyn.net
  5. AJMC. FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause. (2025). ajmc.com